STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

  1. Home
  2. News
  3. JNJ

Johnson & Johnson Stock Price, News & Analysis

JNJ NYSE

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) drives global healthcare innovation through its pharmaceutical, medical technology, and consumer health divisions. This dedicated news hub provides investors and industry professionals with essential updates on regulatory developments, research breakthroughs, and strategic initiatives from one of healthcare's most diversified leaders.

Access real-time press releases and curated analysis covering FDA approvals, clinical trial results, and market expansion efforts. Our repository simplifies tracking JNJ's progress in oncology, immunology, and surgical advancements while maintaining perspective on its long-term corporate strategy.

Key updates include earnings disclosures, product pipeline milestones, and partnership announcements that demonstrate JNJ's commitment to addressing complex health challenges. Bookmark this page for streamlined access to verified information supporting informed decisions about this Dow Jones Industrial Average component.

News

Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) reported strong Q2 2025 results with reported sales growth of 5.8% to $23.7 billion and adjusted EPS of $2.77. The company raised its 2025 guidance, increasing estimated reported sales by $2 billion to 5.4% growth and adjusted EPS to $10.85 at midpoint.

Performance was driven by growth in both segments: Innovative Medicine sales grew 3.8% operationally, led by DARZALEX, CARVYKTI, and TREMFYA, while MedTech sales increased 6.1% operationally, with strong performance in cardiovascular and general surgery products.

Notable achievements include FDA approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, and positive CARVYKTI data in multiple myeloma. The company anticipates significant pipeline progress in H2 2025 across multiple therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
earnings
-
News

Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

Rhea-AI Summary

Johnson & Johnson (NYSE:JNJ) has submitted a supplemental New Drug Application (sNDA) to the FDA for CAPLYTA® (lumateperone) based on impressive Phase 3 trial results in schizophrenia relapse prevention. The study demonstrated a 63% reduction in relapse risk compared to placebo, with significantly longer time to relapse during the 26-week double-blind treatment phase (p=0.0002).

The trial's safety profile remained consistent with existing clinical data, with headache being the most common adverse event. CAPLYTA® is already FDA-approved for schizophrenia treatment and is the first approved therapy for both bipolar I and II depression. The drug's mechanism involves high serotonin 5-HT2A receptor occupancy and lower dopamine D2 receptor occupancy at therapeutic doses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
fda approval
-
News

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

Rhea-AI Summary
Johnson & Johnson (JNJ) announced new data showing IMAAVY (nipocalimab-aahu) demonstrated superior sustained disease control compared to other FcRn blockers in treating generalized myasthenia gravis (gMG). The indirect treatment comparison (ITC) revealed IMAAVY achieved comparable symptom relief at Week 1 and showed greater or statistically significant improvement in MG-ADL scores versus competitors over 24 weeks. IMAAVY, which received FDA approval for treating both adult and pediatric gMG patients aged 12 and older, features a predictable biweekly dosing regimen. The drug showed significantly greater mean improvements versus one comparator at Weeks 8-24 and another at Weeks 10-14, with population-adjusted ITCs showing favorable results for IMAAVY. This data strengthens IMAAVY's position as a treatment option for gMG patients, particularly given its broad approval for both anti-AChR and anti-MuSK antibody positive patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
News

Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit

Rhea-AI Summary
A Suffolk County jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $8 million in damages to Janice Paluzzi, an 84-year-old Massachusetts woman who developed mesothelioma after long-term use of J&J's talcum powder products. The jury found J&J liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talc products caused Paluzzi's terminal cancer. Evidence presented during the trial revealed that J&J had internal knowledge of asbestos contamination in its talc supply for decades but continued marketing the products as safe. The company discontinued talc-based products in the US in 2020. Paluzzi, who used J&J's Baby Powder on herself and her seven children, was diagnosed with mesothelioma in 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
-
News

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Rhea-AI Summary
Johnson & Johnson announced promising results from Phase 2 RedirecTT-1 study evaluating the combination of TALVEY and TECVAYLI in multiple myeloma patients with extramedullary disease (EMD). The study showed a high overall response rate (ORR) of 78.9% in heavily pretreated patients, with 54.4% achieving complete response or better. The trial, involving 90 patients, demonstrated durable responses with 61% of patients progression-free at one year and 74.5% survival rate. The combination therapy showed efficacy even in patients previously treated with BCMA CAR-T therapy (83.3% ORR) or anti-FcRH5 bispecific antibodies (75% ORR). The safety profile aligned with previous monotherapy results, with manageable side effects and low discontinuation rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Rhea-AI Summary
Johnson & Johnson announced promising first clinical data from a Phase 1b study of JNJ-90014496, a novel dual-targeting CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma. The therapy showed impressive efficacy with 80% complete response rate in patients with one prior treatment line and 75% in those with two or more prior treatments. At the recommended Phase 2 dose of 75 million CAR+ T-cells, the therapy demonstrated a favorable safety profile with no Grade 3/4 cytokine release syndrome observed. The study involved 22 patients for efficacy assessment, achieving 100% objective response rate in single prior therapy patients and 92% in multiple prior therapy patients. This development represents a potential advancement over current single-antigen CAR T therapies, which typically achieve only 40% long-term remission rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
earnings
News

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

Rhea-AI Summary
Johnson & Johnson announced promising Phase 1b data for bleximenib (JNJ-75276617), an investigational selective menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid leukemia (AML). The study evaluated 125 patients with KMT2A gene rearrangements or NPM1 gene mutations. At the recommended Phase 2 dose of 100mg twice daily, relapsed/refractory AML patients showed an 82% overall response rate and 59% complete response rate, while newly diagnosed patients achieved 90% and 75% respectively. The safety profile was favorable, with only 4% of patients experiencing differentiation syndrome and no significant QTc prolongation. Common adverse events included nausea (65%), thrombocytopenia (61%), neutropenia (59%), and anemia (49%).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
News

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Rhea-AI Summary
Johnson & Johnson announced significant findings from their Phase 3b APEX study for TREMFYA (guselkumab) in treating active psoriatic arthritis (PsA). The study demonstrated TREMFYA's superior efficacy in inhibiting joint structural damage compared to placebo, with mean vdH-S score changes of 0.55 (Q4W) and 0.54 (Q8W) versus 1.35 for placebo. The drug showed impressive results with over 40% of treated patients achieving ACR50 at Week 24, and approximately 67-68% achieving ACR20. Notably, 63-67% of TREMFYA-treated patients experienced no radiographic progression compared to 53% in the placebo group. The drug also demonstrated significant skin clearance benefits, with 68-73% of treated patients achieving clear or almost clear skin (IGA score 0/1) versus 31% for placebo. TREMFYA maintains its established safety profile with no new safety concerns identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) has announced the election of Daniel Pinto, President of JPMorganChase, to its Board of Directors. Pinto brings extensive financial expertise and deep understanding of global capital markets to JNJ's board. CEO Joaquin Duato emphasized that Pinto's unique perspective and experience will be valuable as the company continues to invest in healthcare innovation. Pinto expressed admiration for JNJ's commitment to scientific innovation and improving health outcomes, stating his honor in joining the board to serve alongside members dedicated to improving global health and well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
management
News

Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients

Rhea-AI Summary
Johnson & Johnson (JNJ) announced promising Phase 1 trial results for JNJ-79635322 (JNJ-5322), a novel trispecific antibody for treating relapsed or refractory multiple myeloma. The trial showed an impressive 86.1% overall response rate among 36 patients at the recommended Phase 2 dose, with 100% response in BCMA and GPRC5D therapy-naive patients. JNJ-5322 uniquely targets three distinct proteins: BCMA and GPRC5D on myeloma cells and CD3 on T-cells. The study involved 126 patients with 8.2 months median follow-up. While cytokine release syndrome occurred in 59% of patients, no cases were Grade 3 or higher. However, 28% experienced Grade 3+ infections, and four treatment-related deaths were reported, including one from adenoviral encephalitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $206.05 as of November 24, 2025.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 491.3B.
Stock JNJ logo
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

#19 Ranked by Market Cap
#1317 Ranked by Dividends

JNJ Stock Data

491.26B
2.41B
0.06%
74.37%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK